PubMed Health⌕ Search

Biomedical subjects

R Weidemann

Publications and source records attributed to R Weidemann.

8 recordsLinked to original sources
PubMed1994

Problems with serum-free production of antithrombin III regarding proteolytic activity and product quality.

Human antithrombin III (AT-III) was produced using a recombinant BHK-21 cell line with a microcarrier culture in spinner flasks. Cells were cultivated for the first 4 days in a medium containing 10% fetal calf serum (FCS). Afterwards, the medium was exchanged and production of AT-III occurred at high cell numbers in a serum-free medium. The product was determined by an immunoassay and further analysed after isolation from the culture medium. During cultivation, high proteolytic activity was detected which caused a considerable product decomposition. Furthermore, a higher level of non-glycosylated AT-III was found after serum-free production.

Animals↗
PubMed1994

Low temperature cultivation--a step towards process optimisation.

Adherent recombinant BHK cells were cultivated at temperatures between 30 and 37 degrees C. Batch and repeated-batch-cultivations in a 2-litre bioreactor showed a significant influence on metabolism and cell growth. The low-temperature-cultivations showed a lower growth rate and a lower glucose consumption rate and, therefore, less lactate production. On the other hand, the maximum cell density and productivity seemed not to be affected by the temperature reduction.

Animals↗
PubMed1990

[Plasmapheresis and/or intermediate high dosage immunoglobulin therapy--effective measures in threatened premature labor and intrauterine hemolysis in anti-PP1Pk (-Tja)?].

Anti-PP1Pk developed by women has been associated with abortion early in pregnancy and hemolytic disease of the newborn. The case of a 19-year-old woman who had had 2 spontaneous abortions in the first trimester is presented. When treated with plasma exchange and substituted with 5% albumin and intravenous immunoglobulin begun at six weeks' gestation and continued until the 30th week, she delivered a viable female infant without anemia. According to our data and review of literature, the effectiveness of therapy by plasmapheresis and/or immunoglobulin is discussed.

Combined Modality Therapy↗